News Press Contact: Kirsten Mabry | (617) 495-4157

Harvard Magazine’s Q&A with Leonardo Riella, the HMS Harold and Ellen Danser Associate Professor of Surgery at Massachusetts General Hospital, on the advancement of xenotransplantation. Reilla discusses what the research and medical teams learned from the first successful kidney transplant using a genetically engineered pig kidney developed by eGenesis, a company founded by HMS Professor George Church and former HMS postdoctoral fellow Luhan Yang with support from the Wyss Institute.

Connie Cepko reflects on four decades of advancing efforts to prevent or treat vision-threatening disease. The Cepko Lab is highly translational, advancing research with support from the Blavatnik Biomedical Accelerator and by collaborating with industry, resulting in over 40 inventions from the lab.

In a recent Guppy Tank event, Professor Jeffrey Smith received feedback from a panel of investors on a new molecule that could help most sun-sensitive patients, research supported by the Blavatnik Biomedical Accelerator. Harvard's Office of Technology Development and LabCentral co-host the Guppy Tank series, where innovators pitch their early-stage concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback.

Attivare, a startup advancing a portfolio of technologies developed at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Massachusetts General Hospital, has shown promising results in cancer clinical trials and is developing a malaria vaccine. Through decades of innovation and cross-disciplinary collaboration, the technology has the potential to fight cancer more effectively or prevent pathogen-related infections.